Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05975983
PHASE2

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Sponsor: InSilico Medicine Hong Kong Limited

View on ClinicalTrials.gov

Summary

The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).

Official title: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Key Details

Gender

All

Age Range

40 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2024-02-08

Completion Date

2026-02-28

Last Updated

2025-11-12

Healthy Volunteers

No

Interventions

DRUG

INS018_055

Pharmaceutical formulation: Tablet Mode of Administration: Oral

DRUG

Placebo

Pharmaceutical formulation: Tablet Mode of Administration: Oral

Locations (12)

University of Alabama at Birmingham

Birmingham, Alabama, United States

HonorHealth Research Institute

Scottsdale, Arizona, United States

Keck School of Medicine of USC

Los Angeles, California, United States

Florida Lung Asthma and Sleep Specialist

Celebration, Florida, United States

Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando

Orlando, Florida, United States

Southeastern Research Center

Winston-Salem, North Carolina, United States

University of Oklahoma Health Sciences Center (OUHSC)

Oklahoma City, Oklahoma, United States

Temple University Hospital-Temple Lung Center

Philadelphia, Pennsylvania, United States

Bogan Sleep Consultants, LLC

Columbia, South Carolina, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Metroplex Pulmonary and Sleep Center

McKinney, Texas, United States

Research Centers of America

McKinney, Texas, United States